All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), anti-PD-(L)1 vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias RFS/DFSdetailed results CheckMate 274 (all population), 2017 0.72 [0.59; 0.88]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.39; 0.78]
0.65 [0.51 ; 0.84 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 40% 991 low not evaluable DMFSdetailed results CheckMate 274 (all population), 2017 0.75 [0.59; 0.95]
CheckMate 274 (PDL1>1%), 2017 0.61 [0.42; 0.89]
0.71 [0.58 ; 0.86 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 0% 991 low not evaluable events or deaths (EFS)detailed results CheckMate 274 (all population), 2017 0.70 [0.55; 0.90]
CheckMate 274 (PDL1>1%), 2017 0.55 [0.35; 0.86]
0.66 [0.53 ; 0.82 ] CheckMate 274 (all population), 2017, CheckMate 274 (PDL1>1%), 2017 2 0% 991 low not evaluable TRAE (any grade)detailed results CheckMate 274 (all population), 2017 2.84 [2.05; 3.92]
2.84 [2.05 ; 3.92 ] CheckMate 274 (all population), 2017 1 0% 709 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.28 [0.95; 1.74]
1.28 [0.95 ; 1.74 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.49 [0.25; 8.98]
1.49 [0.25 ; 8.98 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 2.99 [0.31; 28.90]
2.99 [0.31 ; 28.90 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 2.00 [0.50; 8.06]
2.00 [0.50 ; 8.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Nephritis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 1.99 [0.07; 59.38]
1.99 [0.07 ; 59.38 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 3.98 [0.18; 88.64]
3.98 [0.18 ; 88.64 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 8.01 [0.42; 152.12]
8.01 [0.42 ; 152.12 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 274 (all population), 2017 5.99 [0.30; 120.06]
5.99 [0.30 ; 120.06 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 274 (all population), 2017 0.99 [0.02; 50.11]
0.99 [0.02 ; 50.11 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results CheckMate 274 (all population), 2017 12.09 [0.67; 217.24]
12.09 [0.67 ; 217.24 ] CheckMate 274 (all population), 2017 1 0% 699 NA not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 23:48 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563